^

Health And Family

Moderna or Pfizer booster works better for people vaccinated with J&J — study

Agence France-Presse
Moderna or Pfizer booster works better for people vaccinated with J&J â study
(FILES) In this file photo taken on April 23, 2021 a man receives a dose of the single-dose Johnson & Johnson Janssen Covid-19 vaccine at a vaccine rollout targetting elderly people in Ronda. People who received Johnson & Johnson's Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published October 13, 2021 showed.
AFP/JORGE GUERRERO

WASHINGTON, United States — People who received Johnson & Johnson's Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published Wednesday showed.

The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of "mixing" vaccines — using a different vaccine than the initial doses for the booster shot — which is not currently allowed in the country.

The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna or J&J) for at least 12 weeks.

These three groups were each divided into three new groups to receive one of the available vaccines as a booster. The nine groups consisted of about 50 people each.

Researchers then analyzed antibody levels 15 days after the booster shot.

For people originally inoculated with J&J, antibody levels were four times higher after a J&J booster, 35 times higher after a Pfizer booster and 76 times higher after a Moderna booster.

And antibody levels for those who had originally received Moderna shots were higher "irrespective of the booster vaccine administered," when compared with those who had initially received Pfizer or J&J, the study said.

Additionally, "no safety concerns were identified" after booster doses were administered, it found.

The study, which has not yet been peer-reviewed, has several limitations, however.

The number of participants was small, and the immune response could evolve over time, beyond the 15 days observed during the study.

"Important not to get too carried away with the findings," tweeted Peter Hotez, a professor at Baylor College of Medicine.

Results from trials on a second J&J booster shot conducted by the company itself were "impressive," he said.

The NIH study should fuel discussions by a US Food and Drug Administration (FDA) expert committee, which is scheduled to consider applications for a booster dose from Moderna and J&J on Thursday and Friday, respectively.

A booster from Pfizer has already been approved in the United States for certain populations, such as people aged 65 or older, adults with high-risk medical conditions and those in jobs where they are frequently exposed to the coronavirus.

BOOSTER SHOT COVID-19 VACCINES JOHNSON & JOHNSON MODERNA PFIZER
As It Happens
LATEST UPDATE: October 22, 2021 - 9:05am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

October 22, 2021 - 9:05am

New Zealand sets a 90-percent vaccination target Friday for scrapping lockdowns as Prime Minister Jacinda Ardern unveiled a plan to open up despite the stubborn grip of the Delta variant.

Ardern says her goal had shifted from eliminating Covid-19 to minimising its spread in the community by ramping up vaccinations.

She says the change meant New Zealanders would not be subject to stay-at-home orders and business shutdowns, provided they were fully inoculated.

"We cannot ask vaccinated people to stay home forever," she tells reporters. — AFP

October 15, 2021 - 2:45pm

An expert committee recommends a booster dose of Moderna's anti-Covid vaccine in the United States for certain at-risk groups, a month after making a similar decision for the Pfizer shot.

The opinion submitted by the advisory committee of the Food and Drug Administration -- composed of researchers, epidemiologists and infectious disease experts -- is not binding, but it is rare for the FDA not to follow it. 

After a day of debate, the experts decided to authorize a booster dose of Moderna for three categories of people: the over-65s, people aged between 18 and 64 who are at a higher risk of developing a severe version of the coronavirus, and those whose work may involve frequent exposure to the virus. — AFP

October 13, 2021 - 6:55am

G20 trade ministers on Tuesday promise to work towards a fair distribution of Covid-19 vaccines by lifting export restrictions and making the trade system more transparent.

Their final statement, adopted after a meeting in Sorrento, southern Italy, was a sign of the return of multilateralism, says Italian Foreign Minister Luigi Di Maio.

"We have to ensure that there is greater circulation of vaccines and that there are production factories in the developing countries," French trade minister Franck Riester says. — AFP

October 2, 2021 - 10:22am

COVID vaccinations will be compulsory for all students in California, the state's governor announced Friday — a first in the United States, where vaccine hesitancy has slowed efforts to end the pandemic.

The plan will be phased in as Food and Drug Administration regulators grant full approval for use in younger age groups.

California "will require our kids to get the Covid-19 vaccine to come to school," said Governor Gavin Newsom.

"Our schools already require vaccines for measles, mumps and more. Why? Because vaccines work. This is about keeping our kids safe and healthy."

The Pfizer-BioNTech vaccine has been granted full FDA approval for those age 16 and up. — AFP

September 28, 2021 - 3:45pm

France's pharmaceutical giant Sanofi, which has lagged rivals in producing new generation Covid-19 vaccines, said Tuesday it had decided to halt development of an mRNA candidate and focus on another vaccine against coronavirus.

Despite positive results at phase one and two trials, the candidate will not go to the third and final phase, Sanofi said, as they believed it would arrive too late to market with 12 billion anti-Covid doses already due to be produced by the end of the year.

Results from phase three trials of the other vaccine, developed with Britain's GlaxoSmithKline are expected before the end of 2021. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with